Skip to main content
. 2016 Mar 17;20(7):1381–1391. doi: 10.1111/jcmm.12828

Figure 2.

Figure 2

The expression and enzyme activity of SCAD in the cardiomyocytes treated with tBHP (200 μM, 6 hrs) or siRNA‐1186 (72 hrs). (A) The relative mRNA level of SCAD was significantly inhibited by siRNA‐1186 and tBHP. (B) The relative protein level of SCAD was significantly inhibited by siRNA‐1186 and tBHP. (C) The enzyme activity of SCAD was significantly inhibited by siRNA‐1186 and tBHP. (D) Content of free fatty acid was significantly increased in cardiomyocytes treated with siRNA‐1186 or tBHP. (E) The ATP level was significantly decreased in cardiomyocytes treated with siRNA‐1186 or tBHP. N‐C: negative control siRNA. Mean ± S.D., n = 3, *P < 0.05, **P < 0.01 versus control. ##P < 0.01 versus N‐C.